Investment Rating - The report upgrades the GDP growth forecast for 2025 to 4.5%, reflecting a slight improvement in the economic narrative despite ongoing challenges in real estate and consumption [1][9]. Core Insights - The report highlights that while tariff reductions have eased some external pressures, the underlying deflationary cycle remains entrenched, with nominal GDP growth expected to stay low at around 3.5-3.6% over the next two years [1][46]. - It anticipates a gradual policy response, with potential fiscal stimulus of 0.5-1 trillion RMB aimed at infrastructure and urban renewal projects, alongside expected interest rate cuts by the central bank [2][34]. Summary by Sections Economic Forecasts - The nominal GDP growth rate is projected to be 4.9% in 2023, declining to 3.6% in 2025, while actual GDP growth is expected to be 5.4% in 2023 and 4.5% in 2025 [6]. - Household consumption is forecasted to grow at 4.9% in 2025, supported by government subsidies and policy measures [10]. Policy Measures - The report suggests that the urgency for new incremental policies has decreased, with a focus on utilizing existing policy space and fiscal tools to stimulate the economy [2][34]. - It predicts that the government will implement a supplementary budget of 0.5-1 trillion RMB in Q4 2025 to support key sectors [34]. Inflation and Deflation - The GDP deflator is expected to decline by -0.9% in 2025, indicating persistent deflationary pressures, with PPI deflation and low CPI inflation continuing [46][49]. - The report emphasizes that despite tariff reductions, the overall economic environment remains challenging, with structural issues limiting rapid recovery [9][46]. Trade and Tariffs - The report maintains that U.S. tariffs on China will remain at 30% over the forecast period, which is expected to dampen export growth significantly [20][21]. - It anticipates that China's export growth will drop to 0% in 2025, with a potential rebound to 3.5% in 2026 as tariff impacts lessen [20][23]. Sectoral Insights - Government consumption is projected to rebound significantly, with growth rates expected to rise from 1.4% in 2023 to 7% in 2025, driven by debt restructuring policies [11]. - Infrastructure investment is expected to maintain strong growth, with a forecasted increase from 9.1% in 2023 to over 10% in 2025 [14].

Investment Rating - The report upgrades LYC.AX from Underweight (UW) to Overweight (OW) and ILU from Equal Weight (EW) to Overweight (OW) [5] Core Insights - The humanoid market is projected to reach 0.9 million units and $0.02 trillion by 2030, 134 million units and $1.2 trillion by 2040, and 1,019 million units and $4.7 trillion by 2050, with each humanoid requiring significant amounts of critical minerals [4][11][40] - Cumulative incremental demand for critical minerals could reach up to $800 billion by 2050, with humanoids potentially adding 40% to 167% to the demand for rare earths (specifically NdPr) by 2040 to 2050 [4][16][63] - The report highlights that Chinese enterprises control a significant portion of the supply for critical minerals, necessitating supply chain diversification for western producers [4][21][66] Summary by Sections Humanoid Market Projections - Humanoids could create a market of 0.9 million units and $0.02 trillion by 2030, 134 million units and $1.2 trillion by 2040, and 1,019 million units and $4.7 trillion by 2050 [4][11][40] - Each humanoid is estimated to require approximately 0.9 kg of NdPr, 2 kg of lithium, 6.5 kg of copper, 1.4 kg of nickel, 180 g of cobalt, and 3 kg of graphite [4][11][40] Demand for Critical Minerals - Incremental demand from humanoids could add up to $800 billion across covered critical minerals by 2050, with significant increases in demand for NdPr, lithium, cobalt, and nickel [4][16][63] - By 2050, the annual added demand for critical minerals could be between $50 billion and $120 billion [4][16][63] Supply Chain Dynamics - Chinese enterprises currently control 65% of rare earths, 27% of lithium, approximately 70% of nickel, 55% of cobalt, and 82% of graphite, highlighting the need for diversification in supply chains [4][21][66] - The average lead time for new mines has increased to approximately 17.8 years, posing challenges for meeting rising demand for critical minerals [4][22][66] Price Forecasts and Market Opportunities - The report upgrades long-term price forecasts for rare earths, specifically increasing the NdPr price from $135 per ton to $209 per ton [30][66] - A list of 34 companies is provided for investors to capitalize on the thematic of incremental humanoid demand for critical minerals [5][30]

Investment Rating - The report maintains an "Overweight" (OW) rating for several companies, including Kelun Biotech, WuXi XDC, and Gushengtang, with specific price targets set for each [18][20][22]. Core Insights - Kelun Biotech is expected to have significant data readouts for its TROP2 ADC, with management confident in SKB264's potential as a leading drug. The company is also exploring AI's role in drug discovery, acknowledging its current limitations [3]. - Pharmaron and WuXi XDC show resilience against tariff impacts, with Pharmaron maintaining its FY25 guidance and WuXi XDC expecting minimal cost impacts from tariffs. WuXi XDC aims for 20% of its revenue from commercial projects by 2030 [3]. - AK Medical anticipates a 10-15% CAGR in the orthopedics consumable industry in China and expects mild price cuts during the upcoming VBP renewal, while projecting over 30% sales growth from overseas markets [3]. - Hutchmed is focusing on the sales growth of fruquintinib and sovalitinib, with expected approvals in China for new indications by 2025 and 2026, respectively [4]. - Gushengtang projects 25% revenue growth and 20% adjusted profit growth in FY25, leveraging its self-pay services to mitigate VBP pressures [4]. Summary by Company Kelun Biotech - Expected to present multiple data readouts in 2025, with confidence in SKB264 as a best-in-class drug. AI's role in drug discovery is acknowledged but seen as needing further development [3]. Pharmaron - Maintains FY25 guidance despite geopolitical uncertainties, indicating minimal impact from tariffs due to its service-heavy business model [3]. WuXi XDC - Projects 20% revenue from commercial projects by 2030 and minimal impact from tariffs, with a new Singapore site expected to start operations by the end of 2025 [3]. AK Medical - Expects the orthopedics consumable market to grow at 10-15% CAGR and anticipates mild price cuts during the VBP renewal, with significant overseas sales growth projected [3]. Hutchmed - Focused on fruquintinib and sovalitinib, with expected sales growth and new approvals in China for additional indications [4]. Gushengtang - Projects strong revenue and profit growth, leveraging self-pay services to reduce the impact of VBP pressures [4].

Investment Rating - The report maintains a neutral weight for China within the emerging markets framework, suggesting a focus on stock selection for excess returns [3][17]. Core Insights - Structural improvements in the Chinese market, particularly in corporate return on equity and the emergence of technology leaders, have led to an upward revision of index targets [2][9]. - The report forecasts a moderate recovery in macroeconomic conditions, with a projected nominal GDP growth rate of 3.7% and 3.6% for 2025 and 2026, respectively [17]. - The report emphasizes a preference for offshore markets over A-shares, citing the recent easing of tariff tensions and the potential for the renminbi to appreciate [31][32]. Summary by Sections Market Outlook - The target index levels for June 2026 are set at 78 for the MSCI China Index, 24,500 for the Hang Seng Index, 8,900 for the Hang Seng China Enterprises Index, and 4,000 for the CSI 300 Index, indicating potential upside of 3-5% [2][14][28]. - The report highlights that the offshore Chinese stock indices have outperformed other major markets year-to-date, with the Hang Seng Index and MSCI China Index returning 16% and 15%, respectively [11]. Economic Conditions - The report anticipates that the domestic deflationary environment will persist at least until 2026, with potential fiscal stimulus measures being more moderate than previously expected [12][13]. - The easing of U.S.-China trade tensions is expected to alleviate investor concerns, although geopolitical uncertainties remain a risk [10][17]. Investment Strategy - The report recommends a balanced investment strategy, favoring high-quality large-cap internet and technology stocks while underweighting energy and real estate sectors [3][4]. - It suggests selective holdings in Chinese AI and technology leaders, with a focus on generating excess returns through stock selection [4][17].

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies covered [19]. Core Insights - Consumer activity in China showed improvement in April 2025, although it remained in negative territory. Key indicators such as household loans, passenger car sales, and air passenger travel experienced slight improvements, while retail sales in catering remained stable. However, commodity retail sales weakened due to tariff disruptions [10]. - The effectiveness of the trade-in program has diminished, and the impact of lighter and later additional stimulus may put consumer sentiment under pressure in the coming months [10]. Summary by Relevant Sections Consumer Activity Indicators - The China Five-factor Consumer Activity Z-Score measures the momentum of consumer activity and has shown improvement, correlating positively with the MSCI China index performance [5][6]. - The five factors included in the Z-Score are: household loan year-over-year change, retail sales in catering year-over-year change, retail sales in commodities (excluding autos) year-over-year change, passenger car retail sales year-over-year three-month moving average, and air passenger traffic year-over-year three-month moving average [5]. Economic Context - The report indicates that while consumer activity has improved, the overall sentiment may be affected by external factors such as tariffs and the effectiveness of government stimulus measures [10].

Investment Rating - The report assigns a Neutral rating to Xiaomi (1810) with a price target of HK$60.00, effective until December 31, 2025 [2][5]. Core Insights - Xiaomi has launched its first smartphone (Mi 15S Pro), tablet, and wearable device featuring its self-developed 3nm application processors, alongside a preview of its YU7 SUV vehicle, which is set for pre-orders in July [1][4]. - The initial adoption of Xiaomi's new application processor is expected to be small, with projections of approximately 1 million units in 2025, compared to 25-30 million flagship smartphone shipments [3]. - Xiaomi's commitment to R&D for in-house chips is substantial, with over RMB13.5 billion allocated from 2021 to 2025 and a total of RMB50 billion planned from 2021 to 2030 [3]. - The YU7 SUV boasts impressive performance specifications, including a 0-100 km/h acceleration in 3.23 seconds and a range of 760-835 km across its three variants [4]. Summary by Sections Product Development - The XringO1 application processor is set to debut in Xiaomi's Mi 15S Pro smartphone and Pad7 Ultra Tablet, with a smaller version for its Watch [3]. - The processor is based on TSMC's N3E technology and has shown competitive performance against Apple's A18 Pro in benchmark tests [3]. R&D and Future Prospects - Xiaomi has a dedicated R&D team of 2,500 engineers focused on chip design, indicating a strong commitment to developing in-house silicon [3]. - The company is also working on in-house modem development, which could enhance smartphone performance and adoption [3]. Market Position and Stock Implications - The report suggests that Xiaomi's announcements align with market expectations, although the lack of immediate pricing details for the YU7 may negatively impact the stock in the near term [4]. - The long-term aspirations for in-house silicon appear more aggressive than previously anticipated, which could influence investor sentiment [4][5].

Investment Rating - The report assigns an "Overweight" (OW) rating to Microsoft (MSFT) [7] Core Insights - The impacts on Microsoft from OpenAI's rapid growth and valuation are underappreciated by investors, with a significant EPS acceleration story expected in FY27 [1][9] - The report emphasizes the attractive risk/reward profile for Microsoft, particularly in light of its investments in Generative AI and the expected acceleration in Azure business [1][18] Summary by Sections 1) Equity Method Accounting Implications - Microsoft's investments in OpenAI are recorded at cost, with losses from OpenAI impacting Microsoft's EPS until profitability is achieved or the $13 billion cap is reached [2][60] - The evolving partnership may lead to changes in accounting for transactions between Microsoft and OpenAI [2][40] 2) Azure AI Growth Potential - OpenAI's rapid growth is expected to drive significant upside in Azure AI estimates, contributing 49% of Azure AI's growth in CY25 and over 100% in CY26 [3][12] - If the 'Other' portion of Azure AI revenue grows by 50% in CY26, overall Azure revenue could sustain approximately 35% YoY growth, exceeding current estimates [3][12] 3) Valuation and Market Position - Microsoft shares are trading at a discount to peers, with a current P/E of 28X CY26 GAAP EPS, which does not reflect the company's strong positioning and growth potential [9][18] - The report suggests that excluding OpenAI-related losses from valuation metrics could reveal a more favorable outlook for Microsoft shares [9][18] 4) Revenue Forecasts - OpenAI is forecasted to generate $12.7 billion in revenue for CY25 and $33.6 billion for CY26 [10] - Azure AI is projected to achieve revenues of $18.2 billion in CY25 and $30.5 billion in CY26 [12] 5) Investment Drivers - Key drivers for Microsoft's growth include strong positioning in public cloud adoption, large distribution channels, and expanding margins, supporting mid- to high-teens total return profiles long-term [25][26] - The report highlights the durability of Azure growth and the adoption of higher-priced O365 Commercial SKUs as critical factors for revenue growth [24][25]

Investment Rating - The industry investment rating is "In-Line" [7] Core Insights - Foryou (002906.SZ) is expected to be the major beneficiary of Xiaomi's YU7 launch, with an estimated annual revenue growth of 10-15% from supplying the panoramic head-up display (P-HUD) [2] - The introduction of P-HUD technology by other OEMs like BMW may further enhance Foryou's growth potential [2] - Other companies that may benefit from the YU7 launch include Tuopu (601689.SS), Desay (002920.SZ), and Xingyu (601799.SS) [10] Summary by Relevant Sections Company Analysis - Foryou Corporation (002906.SZ) is projected to experience significant revenue growth due to its involvement in the YU7 project, marking a shift from not supplying HUD for Xiaomi's first EV, SU7 [2] - Tuopu (601689.SS) supplies air suspension for both SU7 and YU7, with a value content of Rmb6-8K per vehicle [10] - Desay (002920.SZ) is likely to become the autonomous domain controller supplier for YU7, leveraging the NVIDIA Thor chip [10] - Xingyu (601799.SS) has not supplied to YU7 but is positioned to win future orders from Xiaomi [10] Market Trends - The adoption of P-HUD technology is anticipated to grow, with potential for increased orders from other manufacturers following Xiaomi and BMW's lead [2] - The overall market for auto parts in the EV sector is expected to expand, driven by technological advancements and increasing consumer demand for smart features [2]

Investment Rating - The report maintains an equal-weight rating on China within the Emerging Markets/Asia Pacific ex-Japan framework, indicating a balanced approach to investment opportunities in the region [15]. Core Insights - The sentiment for A-shares has declined, with the weighted Morgan Stanley A-share Sentiment Indicator (MSASI) dropping to 61%, a decrease of 10 percentage points from the previous cutoff date [2][6]. - Despite the drop in sentiment, index targets for Chinese equities have been raised due to sustained structural improvements and positive developments in tariffs and earnings [14]. - The report suggests a preference for offshore investments over A-shares, citing a stronger positioning to benefit from current market conditions [15]. Summary by Sections A-Share Market Sentiment - A-share investor sentiment has decreased, with the simple MSASI falling to 49%, a drop of 13 percentage points compared to the prior cutoff date [2]. - Average daily turnover for various segments, including ChiNext and A-shares, has also seen declines, with ChiNext turnover down by 20% [2]. Macro Economic Outlook - The economics team has revised GDP growth forecasts for 2025 and 2026 to 4.5% and 4.2% respectively, reflecting stronger tracking for 2Q GDP due to reduced tariff headwinds [4]. - However, domestic investment and consumption have missed expectations, with capital expenditure slowing broadly, particularly in manufacturing [4]. Property Market Insights - Property sales have shown a deeper year-on-year decline in April, with construction activity worsening, indicating potential for a faster decline in the physical market in the coming months [5]. Investment Strategy - The report emphasizes a focus on high-quality large-cap internet and tech leaders while underweighting sectors such as energy and real estate [15]. - The structural improvements in China's equity market since the second half of 2024 are believed to remain intact, despite broader macro-level recovery challenges [13][14].

Investment Rating - The report initiates coverage on Pop Mart with an "Overweight" (OW) rating and sets a price target of HK$250 for June 2026, which implies a PEG of 1.3x and a P/E of 32.6x for 2026 [1][4][9]. Core Insights - Pop Mart is positioned as a leader in China's rapidly growing IP merchandise market, boasting a portfolio of over 100 owned and licensed IPs, 521 retail stores, and 2,472 roboshops across more than 30 countries. The company is also leveraging major online platforms for sales [1][8]. - The report highlights two main reasons for favoring Pop Mart: its strong IP offerings, particularly the rising 'super IP' Labubu, and its ambitious global expansion plans, with overseas sales projected to grow at a 42% CAGR from 2025 to 2027, contributing 65% of total sales by 2027 [1][8]. - Forecasts indicate a sales CAGR of 44% and an earnings CAGR of 56% from 2024 to 2027, driven by strong IP, store openings, improved productivity, and margin expansion [1][8]. Summary by Sections Market Position and Strategy - Pop Mart leads the IP merchandise market in China, with significant growth potential in overseas markets, particularly in North America and Europe, where sales surged 480% year-over-year in Q1 2025 [5][8]. - The company aims to capitalize on its strong IP portfolio and global expansion strategy, with expectations of overseas sales growth outpacing domestic growth [5][8]. Financial Projections - The report projects revenue growth from Rmb 13,038 million in FY24 to Rmb 39,335 million in FY27, with an adjusted EBITDA margin increasing from 38.5% to 43.9% over the same period [7][8]. - Adjusted EPS is expected to grow from 2.42 in FY24 to 9.13 in FY27, reflecting a strong upward trajectory in profitability [7][8]. Valuation Metrics - The price target of HK$250 is based on a PEG ratio of 1.3x, which is a 20% discount compared to similar companies in the market [9]. - The DCF-based fair value estimate ranges from HK$226 to HK$327, indicating a favorable valuation compared to peers [9]. Competitive Analysis - The report compares Pop Mart with established players like Sanrio, highlighting Pop Mart's rapid growth in brand recognition and market share, particularly with its IP Labubu, which is seen as a potential competitor to Hello Kitty [5][17][29]. - The analysis indicates that while Sanrio has a long-established presence, Pop Mart's innovative marketing and product strategies are driving significant consumer interest and engagement [5][29].